Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib eye drops vs Ranibizumab in neovascular AMD
NCT01134055Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2010
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of pazopanib in neovascular age-related macular degeneration (NVAMD), sponsored by GSK. Started Jun 2010; status: completed.
02
Drugs
pazopanib
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01134055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01134055.